PERSERIS KIT

LOE Approaching

risperidone

NDASUBCUTANEOUSFOR SUSPENSION, EXTENDED RELEASE
Approved
Jul 2018
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
20

Mechanism of Action

risperidone, in schizophrenia, is unclear. The drug's therapeutic activity in schizophrenia could be mediated through a combination of dopamine Type 2 (D 2 ) and serotonin Type 2 (5HT 2 ) receptor antagonism. The clinical effect from risperidone results from the combined concentrations of…

Clinical Trials (5)

NCT04418466Phase 1/2Completed

Safety, Tolerability, and Pharmacokinetics of Switching From Oral Risperidone to Risperidone Implant

Started Apr 2021
NCT03978832Phase 4Completed

Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone

Started Jun 2019
69 enrolled
Schizophrenia
NCT03713658Phase 4Completed

A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities

Started Oct 2018
34 enrolled
Schizophrenia
NCT03390712N/AUnknown

Mirror-image Study of Paliperidone Palmitate and Risperidone Long-acting Injection

Started Jan 2018
328 enrolled
Schizophrenia Spectrum and Other Psychotic Disorders
NCT02758067Phase 3Withdrawn

Comparison of the Effectiveness of Brexpiprazole With That of Risperidone

Started Jun 2016
0
Schizophrenia

Loss of Exclusivity

LOE Date
Feb 13, 2028
23 months away
Patent Expiry
Feb 13, 2028

Patent Records (5)

Patent #ExpiryTypeUse Code
10406160
Jun 26, 2026
Product
U-2608
10058554
Sep 26, 2026
U-2363
9597402
Sep 26, 2026
Product
11110093
Nov 5, 2026
Product
U-3135
11013809
Feb 13, 2028
Product
U-3135